| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Cortactin binding protein 1, Cortactin SH3 domain-binding protein, Cortactin-binding protein 1, CortBP1, CTTNBP1, GKAP/SAPAP interacting protein, GKAP/SAPAP-interacting protein, KIAA1022, Proline rich synapse associated protein 1, Proline-rich synapse-associated protein 1, ProSAP1, SH3 and multiple ankyrin repeat domains protein 2, SHAN2_RAT, Shank2, SPANK-3 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Fusion protein amino acids 84-309 of rat Shank2 |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
SHANK proteins are a family of postsynaptic scaffolding proteins that organize receptor and signaling complexes at excitatory synapses. They contain multiple protein interaction domains, including ankyrin repeats, SH3, PDZ, and SAM domains, enabling them to link neurotransmitter receptors to the actin cytoskeleton.
SHANK proteins regulate synaptic strength, dendritic spine morphology, and receptor trafficking. Disruption of SHANK-mediated scaffolding impairs glutamate receptor localization and contributes to synaptic loss—a key feature of Alzheimer’s disease.
SHANK family members also influence receptor tyrosine kinase signaling and are involved in neurodevelopmental processes. Their dysregulation has been associated with autism spectrum disorders, schizophrenia, and intellectual disability, making them central to both neurodevelopmental and neurodegenerative research.
1 µg/ml of SMC-327 was sufficient for detection of Shank1-4 in 10 µg of rat brain lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-327D — Size: 100 ug: SHANK Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-327D, RRID: AB_2301756)
- SMC-327D-A390 — Size: 100 ug: SHANK Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-327D-A390, RRID: AB_2700431)
- SMC-327D-A488 — Size: 100 ug: SHANK Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-327D-A488, RRID: AB_2700432)
- SMC-327D-A594 — Size: 100 ug: SHANK Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-327D-A594, RRID: AB_2700434)
- SMC-327D-APC — Size: 100 ug: SHANK Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-327D-APC, RRID: AB_2700440)
- SMC-327D-BI — Size: 100 ug: SHANK Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-327D-BI, RRID: AB_2700441)
- SMC-327D-FITC — Size: 100 ug: SHANK Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-327D-FITC, RRID: AB_2700442)
- SMC-327D-HRP — Size: 100 ug: SHANK Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-327D-HRP, RRID: AB_2700443)
- SMC-327D-PCP — Size: 100 ug: SHANK Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-327D-PCP, RRID: AB_2700445)
- SMC-327D-RPE — Size: 100 ug: SHANK Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-327D-RPE, RRID: AB_2700446)
- SMC-327S — Size: 12 ug: SHANK Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-327S, RRID: AB_2301756)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Kim J.H., et al. (2009) Exp Mol Med. 41(4): 236-242.
3. Gong Y., et al. (2009) Brain Res. 1292: 191-198.